Coronary sinus reducer implantation for the treatment of chronic refractory angina The primary effectiveness endpoint was an improvement in canadian cardiovascular society (ccs) class at 6 months. The aim of this study is to examine the safety and efficacy of the coronary sinus (cs) reducer in improving angina severity and quality of life in patients suffering from angina pectoris, refractory to medical and interventional therapies. The coronary sinus reducer (csr) is proposed to reduce angina in patients with stable coronary artery disease by improving myocardial perfusion We aimed to measure its efficacy, compared with placebo, on myocardial ischaemia reduction and symptom improvement. The very interesting and extremely powerful report by giannini et al
The coronary sinus (cs) reducertm (neovasc inc., richmond bc, canada) is designed to reduce disabling symptoms and improve quality of life of patients suffering from refractory angina (table 1).
OPEN
